DOA
EDIT icon

D'Orazio & Associates’s Editas Medicine EDIT Stock Holding History

D'Orazio & Associates’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-88
Closed -$3K – 284
2018
Q2 		$3K Hold
88
– – ﹤0.01% 238
2018
Q1 		$3K Hold
88
– – ﹤0.01% 252
2017
Q4 		$3K Buy
+88
New +$2.22K ﹤0.01% 285

Other funds holding EDIT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

D'Orazio & Associates's EDIT Position: Q3 2018 in Review

D'Orazio & Associates sold out of Editas Medicine (EDIT) in Q3 2018, closing a stake of 88 shares — an estimated $3K sold.

D'Orazio & Associates first reported a position in EDIT in Q4 2017 and held it in 3 quarters. The position peaked at $3K in Q2 2018. 199 funds tracked by Wall St. Rank hold EDIT as of Q3 2018.

  • D'Orazio & Associates reported no remaining Editas Medicine position as of Q3 2018 after selling out during the quarter.
  • D'Orazio & Associates sold 88 Editas Medicine shares in Q3 2018, an estimated $3K.
  • D'Orazio & Associates first reported a position in Editas Medicine in Q4 2017 and held it in 3 quarters.
  • D'Orazio & Associates's Editas Medicine position peaked at $3K in Q2 2018.
  • 199 funds tracked by Wall St. Rank held Editas Medicine as of Q3 2018.

Based on D'Orazio & Associates's 13F filing for Q3 2018, filed 13 Nov 2018.